Results 1 to 10 of about 34,600 (114)

A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity [PDF]

Cells, 2021
Type II DNA topoisomerase (topo II) is an essential nuclear enzyme and a well-validated anticancer drug target. Previously, we have carried out several rounds of structural optimizations on our in-house topo II inhibitor E17, which was shown to have ...
Zhi-Ying Li, Guang-Sen Xu, Xun Li
doaj   +2 more sources

New thiazole derivative as a potential anticancer and topoisomerase II inhibitor [PDF]

Scientific Reports
To shed light on the significance of thiazole derivatives in the advancement of cancer medication and to contribute to therapeutic innovation, we have designed the synthesis and antiproliferative activity investigation of 5-(1,3-dioxoisoindolin-2-yl)-7 ...
Mayada I. Shosha, Fawzia Z. El-Ablack, Entsar A. Saad   +2 more
doaj   +2 more sources

Amonafide Targeting NTSR1‐PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Pulmonary arterial hypertension (PAH) is a progressive disease driven by pulmonary vascular remodeling, largely due to the abnormal proliferation and phenotypic switching of pulmonary artery smooth muscle cells. Methods Levels of topoisomerase
Yong‐Jian Zhu, Jie‐Jian Kou, Ya‐Cong Bo, Meng‐Jie Zhang, Xin Fan, Lu‐Ling Zhao, Yi Yan, Hong‐Da Zhang, Wen‐Hui Wu, Ping Yuan, Yan Liu, Jun‐Zhuo Shi, Xiao‐Bin Pang, Yang‐Yang He   +13 more
doaj   +2 more sources

A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review [PDF]

Cancer Medicine
Background Etoposide is a semisynthetic derivative of podophyllotoxin and an FDA‐approved topoisomerase II inhibitor that induces DNA strand breaks leading to cancer cell death. Cervical cancer remains the fourth most common cancer among women worldwide,
Nikitha Kotian, Yashaswini Reddy, Padmini Pai, Babitha Kampa Sundara   +3 more
doaj   +2 more sources

Case Report: Two cases of secondary malignant neoplasms following treatment in pediatric patients [PDF]

Frontiers in Pediatrics
Among the various long-term iatrogenic sequelae associated with the treatment of pediatric and adolescent patients with malignancies, secondary malignant neoplasms (SMNs) are among the greatest concerns.
Yue Wang, Huan Zhang, Qiuling Miao, Li Li, Fang Xu, Xiaoning Mao, Xianping Jiang   +6 more
doaj   +2 more sources

Identification of anziaic acid, a lichen depside from Hypotrachyna sp., as a new topoisomerase poison inhibitor. [PDF]

PLoS ONE, 2013
Topoisomerase inhibitors are effective for antibacterial and anticancer therapy because they can lead to the accumulation of the intermediate DNA cleavage complex formed by the topoisomerase enzymes, which trigger cell death.
Bokun Cheng, Shugeng Cao, Victor Vasquez, Thirunavukkarasu Annamalai, Giselle Tamayo-Castillo, Jon Clardy, Yuk-Ching Tse-Dinh   +6 more
doaj   +1 more source

Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases

Viruses, 2022
Although many arenaviruses cause severe diseases with high fatality rates each year, treatment options are limited to off-label use of ribavirin, and a Food and Drug Administration (FDA)-approved vaccine is not available.
Tosin Oladipo Afowowe, Yasuteru Sakurai, Shuzo Urata, Vahid Rajabali Zadeh, Jiro Yasuda   +4 more
doaj   +1 more source

First-in-Class, Thiosemicarbazide-Based, Dual Inhibitors of Human DNA Topoisomerase IIα and Indoleamine-2,3-Dioxygenase 1 (IDO-1) with Strong Anticancer Properties

Medical Sciences Forum, 2022
According to a WHO report from 2020, cancer constitutes one of the leading causes of death worldwide. The number of cancer deaths is estimated to be approximately 10 million per year.
Barbara Kaproń, Tomasz Plech
doaj   +1 more source

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

Nature Communications, 2021
CX-5461 recently progressed through phase I clinical trial as a first-inhuman inhibitor of RNA-POL I. Here, the authors demonstrate that CX-5461 synergizes with topoisomerase I inhibitors to inhibit neuroblastoma cells and that its primary target in this
Min Pan, William C. Wright, Richard H. Chapple, Asif Zubair, Manbir Sandhu, Jake E. Batchelder, Brandt C. Huddle, Jonathan Low, Kaley B. Blankenship, Yingzhe Wang, Brittney Gordon, Payton Archer, Samuel W. Brady, Sivaraman Natarajan, Matthew J. Posgai, John Schuetz, Darcie Miller, Ravi Kalathur, Siquan Chen, Jon Patrick Connelly, M. Madan Babu, Michael A. Dyer, Shondra M. Pruett-Miller, Burgess B. Freeman, Taosheng Chen, Lucy A. Godley, Scott C. Blanchard, Elizabeth Stewart, John Easton, Paul Geeleher   +29 more
doaj   +1 more source

Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. [PDF]

PLoS ONE, 2009
BACKGROUND:Natural product structures have high chemical diversity and are attractive as lead structures for discovery of new drugs. One of the disease areas where natural products are most frequently used as therapeutics is oncology. METHOD AND FINDINGS:
Walid Fayad, Mårten Fryknäs, Slavica Brnjic, Maria Hägg Olofsson, Rolf Larsson, Stig Linder   +5 more
doaj   +1 more source